Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial.
OBJECTIVE
To study the therapeutic efficacy of a Chinese and Western integrated regimen, killing Helicobacter pylori quadruple therapy on H pylori-associated peptic ulcers (PU).


METHODS
With prospective and double-blind controlled method, seventy-five active PU patients with H pylori infection were randomized to receive one of the following three regimens: (1) new triple therapy (group A: lansoprazole 30 mg qd, plus clarithromycin 250 mg bid, plus amoxycillin 500 mg tid, each for 10 d); (2) killing Hp quadruple therapy(group B: the three above drugs plus killing H pylori capsule 6 capsules bid for 4 wk) and (3) placebo(group C: gastropine 3 tablets bid for 4 wk). H pylori eradication and ulcer healing quality were evaluated under an endoscope 4 wk after treatment. The patients were followed up for 5 years.


RESULTS
Both the healing rate of PU and H pylori eradication rate in group B were significantly higher than those in group C (100% and 96.4% vs 20% and 0%, respectively, P<0.005), but there was no significant difference compared to those in group A (88% and 92%, P>0.05). The healing quality of ulcer in group B was superior to that in groups C and A (P<0.05). The recurrence rate of PU in group B (4%) was lower than that in group A (10%) and group C (100%, P<0.01).


CONCLUSIONS
Killing Helicobacter pylori quadruple therapy can not only promote the eradication of H pylori and healing quality of ulcer but also reduce recurrence rate of ulcer.
Feng
Li-Ying
LY
Department of Internal Medicine, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China. ffly513@sohu.com
Yao
Xi-Xian
XX
Jiang
Shu-Lin
SL
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D011446:Prospective Studies; D012008:Recurrence; D014945:Wound Healing / Q000187:drug effects
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D004365:Drugs, Chinese Herbal; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole
Am J Gastroenterol. 2003 Oct;98(10):2149-56
14572560
Aliment Pharmacol Ther. 2002 Apr;16 Suppl 2:204-9
11966543
J Lab Clin Med. 2003 Dec;142(6):421-30
14713894
J Clin Gastroenterol. 1997;25 Suppl 1:S229-34
9479653
J Clin Gastroenterol. 1991;13 Suppl 1:S42-7
1719066
Baillieres Best Pract Res Clin Gastroenterol. 2000 Feb;14(1):133-45
10749094
Gastroenterology. 1991 Nov;101(5):1187-91
1936788
Eur J Gastroenterol Hepatol. 1999 Aug;11 Suppl 2:S35-7; discussion S43-5
10503821
Helicobacter. 1999 Jun;4(2):106-12
10382124
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1996 Aug;16(8):508-10
9387755
Aliment Pharmacol Ther. 2003 May 1;17(9):1125-35
12752349
Dig Dis Sci. 1998 Sep;43(9 Suppl):99S-106S
9753234